Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2023-11-22
2024-11-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators have developed an exergame, using an augmented reality (AR) headset, which will eventually offer a new form of rehabilitation, both fun and interactive, for children and teenagers with CP or ABIs.
Principal Objective:
Assessing the usability of an AR exercise game for children with CP or ABI.
Secondary Objectives:
Evaluating the user experience (attractiveness, emotions) of an AR exergame for children with CP or ABI Evaluating the acceptance of an AR exergame before and after its use in children with CP or ABI To assess the intrinsic motivation associated with AR exercise for CP and ABI children.
To assess the fatigue (mental and physical) associated with exercise in RA in children with CP or ABI.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy
NCT06096272
Virtual Rehabilitation Innovations for Motivation
NCT04430673
Feedback in Augmented Reality to Control of Gait Parameters in Children With Cerebral Palsy
NCT04460833
Efficacy Study of an Interactive Robot for the Rehabilitation of the Upper Limb in Children With Cerebral Palsy
NCT01700153
Intensive Rehabilitation Program for Upper Limb in Children and Adolescents With Cerebral Palsy
NCT07285837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* V0 → Pre-inclusion visit carried out during a follow-up consultation (routine care): carried out by the investigator during which a clinical examination to check the inclusion and non-inclusion criteria will be performed. The child and his/her legal guardians are informed of the study (24-hour cooling-off period), and are given a written consent form.
* V1 → Inclusion visit + session 1: Collection of signed consent form and opening of data collection file
The session lasts approximately 2h15 (including breaks) and includes :
i. A pre-session evaluation with : Clinical tests (walking parameters with the helmet (walking speed, step length) + Eyetracking), an acceptance questionnaire before using the device, and a pre-session fatigability scale.
ii. The main body of the session is made up of a phase in which the children familiarise themselves with one of the mini games + a phase of use.
iii. A post-session evaluation with : A questionnaire on usability, user experience, acceptance after using the device, motivation and fatigue after the session.
\- V2 → Session 2 (second mini-game): The session lasts approximately 2 hours (including breaks) and includes: i. A pre-session evaluation with : A pre-use acceptance questionnaire and a pre-session fatigue scale ii. The main body of the session is made up of a phase in which the children familiarise themselves with the second mini-game + a phase of use.
iii. A post-session evaluation with : A questionnaire on usability, user experience, acceptance after using the device, motivation and fatigue after the session.
The order of the mini-games is randomised between participants
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
exergames
There are two exergames: corsi and zoo games
Augmented reality-based programme/Microsoft Hololens version 2
Participants play two exergames, the aim of this process is to engage cognitive double tasks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Augmented reality-based programme/Microsoft Hololens version 2
Participants play two exergames, the aim of this process is to engage cognitive double tasks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Children with sufficient listening comprehension skills
* Membership of the French social security system
* Children who have given their consent
* Obligation to obtain written informed consent from legal representatives
Exclusion Criteria
* Children with contraindications to the use of new technologies (e.g. photosensitive epilepsy)
* Children with atypical or uncorrected visual and/or hearing impairment
* Children with unstable medical conditions
* Simultaneous participation in another research protocol that could have an influence on the evaluation of the PLAR system
* Refusal by the child or the family
10 Years
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Esquirol
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Julia HAMONET-TORNY
Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julia HAMONEt-TORNY, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Esquirol
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Julia HAMONET-TORNY
Limoges, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A00904-41
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.